NCT03318445: Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

NCT03318445
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Tumors must have one of the following DNA repair defects: BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L
Exclusions: Poorly controlled or symptomatic CNS metastases or carcinomatous meningitis- see trial for details
https://ClinicalTrials.gov/show/NCT03318445

Comments are closed.

Up ↑